多参数MRI与影像组学预测HER2零表达、低表达及阳性乳腺癌
该研究在两家中心纳入接受乳腺MRI的乳腺癌女性(训练集208例,外部测试集131例),基于T2加权和动态增强T1加权图像提取影像组学特征并构建标签; 外部测试集中该标签区分HER2低表达及阳性 versus HER2零表达肿瘤的AUC为0.80(95%CI: 0.71, 0.89),比值比为7.6(95%CI: 2.9, 19.8; P < .001); 在HER2低表达或阳性乳腺癌中,组织学类型、MRI上相关非肿块强化及多发病灶预测HER2阳性 versus 低表达的AUC为0.77(95%CI: 0.68, 0.86)。
要点
- 影像组学标签区分HER2低表达及阳性 versus HER2零表达肿瘤,外部测试集AUC为0.80(95%CI: 0.71, 0.89)。
- 组织学类型、相关非肿块强化及多发病灶预测HER2阳性 versus 低表达,外部测试集AUC为0.77(95%CI: 0.68, 0.86)。
- 多参数乳腺MRI的影像组学标签及肿瘤描述符可能预测乳腺癌不同的HER2表达状态。
核心结论
- 多参数乳腺MRI的影像组学标签及肿瘤描述符可能预测乳腺癌不同的HER2表达状态,具有治疗意义。
研究设计与样本
- 研究纳入2020年12月至2022年12月期间在两家中心接受MRI的乳腺癌女性。
- 训练集为来自中心1的208例患者(平均年龄53岁±14[标准差])。
- 外部测试集为来自中心2的131例患者(平均年龄54岁±13)。
- 在T2加权和动态增强T1加权图像上进行肿瘤分割和影像组学特征提取。
- 采用可重复特征的无监督相关分析和最小绝对收缩和选择算子进行特征选择以构建影像组学标签。
关键影像表现/征象
- 在HER2低表达或阳性乳腺癌中,MRI上的组织学类型、相关非肿块强化及多发病灶可用于预测HER2阳性 versus 低表达。
诊断标准与关键数值
- HER2零表达定义为免疫组化(IHC)评分为0。
- HER2低表达定义为IHC评分为1+或2+且荧光原位杂交(FISH)阴性。
- HER2阳性定义为IHC评分为2+且FISH阳性或IHC评分为3+。
- 外部测试集中,影像组学标签区分HER2低表达及阳性 versus HER2零表达肿瘤的AUC为0.80(95%CI: 0.71, 0.89),比值比为7.6(95%CI: 2.9, 19.8; P < .001)。
- 外部测试集中,组织学类型、相关非肿块强化及多发病灶预测HER2阳性 versus HER2低表达的AUC为0.77(95%CI: 0.68, 0.86)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Half of breast cancers exhibit low expression levels of human epidermal growth factor receptor 2 (HER2) and can be targeted by new antibody-drug conjugates. The imaging differences between HER2-zero (immunohistochemistry [IHC] score of 0), HER2-low (IHC score of 1+ or 2+ with negative findings at fluorescence in situ hybridization [FISH]), and HER2-positive (IHC score of 2+ with positive findings at FISH or IHC score of 3+) breast cancers were unknown. Purpose To assess whether multiparametric dynamic contrast-enhanced MRI-based radiomic features can help distinguish HER2 expressions in breast cancer. Materials and Methods This study included women with breast cancer who underwent MRI at two different centers between December 2020 and December 2022. Tumor segmentation and radiomic feature extraction were performed on T2-weighted and dynamic contrast-enhanced T1-weighted images. Unsupervised correlation analysis of reproducible features and least absolute shrinkage and selector operation were used for the selection of features to build a radiomics signature. The area under the receiver operating characteristic curve (AUC) was used to assess the performance of the radiomic signature. Multivariable logistic regression was used to identify independent predictors for distinguishing HER2 expressions in both the training and prospectively acquired external data set. Results The training set included 208 patients from center 1 (mean age, 53 years ± 14 [SD]), and the external test set included 131 patients from center 2 (mean age, 54 years ± 13). In the external test data set, the radiomic signature achieved an AUC of 0.80 (95% CI: 0.71, 0.89) for distinguishing HER2-low and -positive tumors versus HER2-zero tumors and was a significant predictive factor for distinguishing these two groups (odds ratio = 7.6; 95% CI: 2.9, 19.8; P < .001). Among HER2-low or -positive breast cancers, histology type, associated nonmass enhancement, and multiple lesions at MRI had an AUC of 0.77 (95% CI: 0.68, 0.86) in the external test set for the prediction of HER2-positive versus HER2-low cancers. Conclusion The radiomic signature and tumor descriptors from multiparametric breast MRI may predict distinct HER2 expressions of breast cancers with therapeutic implications. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kataoka and Honda in this issue.
引用
- Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology. 2023. PMID: 37526540. doi:10.1148/radiol.222646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。